Gene therapy of benign gynecological diseases

Advanced Drug Delivery Reviews

Volumn 61, Issue 10, 2009, Pages 822-835

  Hassan, Memy H ^a   Othman, Essam E ^b   Hornung, Daniela ^c   Al Hendy, Ayman ^d  

^a Al Azhar University   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Adenovirus; Endometriosis; Gene therapy; Uterine leiomyoma

Indexed keywords

ADENOVIRUS; ANTIANGIOGENESIS; ENDOMETRIOSIS; GENE THERAPY; GENETIC MATERIALS; LEIOMYOMA; MOLECULAR TARGETS; PRECLINICAL STUDIES; SIDE EFFECT; THERAPEUTIC BENEFITS; UTERINE LEIOMYOMA; UTERINE LEIOMYOMAS;

BIOCHEMISTRY; DRUG DELIVERY; GENE TRANSFER; MOLECULAR BIOLOGY; ONCOGENIC VIRUSES;

GENES;

ADENOVIRUS VECTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; DOUBLE STRANDED DNA; ESTROGEN RECEPTOR; FLUCYTOSINE; GANCICLOVIR; LENTIVIRUS VECTOR; LIPOSOME; NAKED DNA; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PARVOVIRUS VECTOR; PLASMID DNA; RETROVIRUS VECTOR; THYMIDINE KINASE; VIRUS VECTOR;

BONE MARROW SUPPRESSION; CANCER RESISTANCE; CLINICAL TRIAL; DRUG CYTOTOXICITY; ENDOMETRIOSIS; GENE MUTATION; GENE TARGETING; GENE THERAPY; GYNECOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOPOTENTIATION; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR; UTERUS MYOMA; UTERUS SURGERY; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALS; ENDOMETRIOSIS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LEIOMYOMA;

EID: 67649224010     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.04.023     Document Type: Review

References (140)

1. Trent R.J.A., and Alexander I.E. Clinical perspectives gene therapy: applications and progress towards the clinic. Int. Med. J. 34 (2004) 621-625
2. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C.A., Ramsey W.J., Muul L., Morgan R.A., and Anderson W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270 (1995) 475-480
3. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
4. Al-Hendy A., and Salama S. Gene therapy and uterine leiomyoma: a review. Hum. Reprod. Updat. 12 (2006) 385-400
5. Somia N., and Verma I.M. Gene therapy: trials and tribulations. Nat. Rev., Genet. 2 (2000) 91-99
6. Mehier-Humbert S., and Guy R.H. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv. Drug Deliv. Rev. 57 (2005) 733-753
7. Nishikawa M., and Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 12 (2001) 861-870
8. Hendrie P.C., and Russell D.W. Gene targeting with viral vectors. Molec. Ther. 12 (2005) 9-17
9. Benn S.I., Whitsitt J.S., Broadley K.N., Nanney L.B., Perkins D., He L., Patel M., Morgan J.R., Swain W.F., and Davidson J.M. Particle-mediated gene transfer with transforming growth factor-beta1 cDNAs enhances wound repair in rat skin. J. Clin. Invest. 98 (1996) 894-902
10. Davidson J.M., Krieg T., and Eming S.A. Particle-mediated gene therapy of wounds. Wound Repair Regen. 8 (2000) 452-459
11. Mir L.M., Moller P.H., Andrée F., and Gehl J. Electric pulse-mediated gene delivery to various animal tissues. Adv. Genet. 54 (2005) 83-114
12. Pack D.W., Hoffman A.S., Pun S., and Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4 (2005) 581-593
13. Abdelhady H.G., Allen S., Davies M.C., Roberts C.J., Tendler S.J., and William P.M. Direct real-time molecular scale visualisation of the degradation of condensed DNA complexes exposed to DNase I. Nucleic Acids Res. 31 (2003) 4001-4005
14. Worgall S.A. Realistic chance for gene therapy in the near future. Pediatr. Nephrol. 20 (2005) 118-124
15. Barnett B.G., Crews C.J., and Douglas J.T. Targeted adenoviral vectors. Biochim. Biophys. Acta 1575 (2002) 1-14
16. Meier O., and Greber U.F. Adenovirus endocytosis. J. Gene Med. 5 (2003) 451-462
17. Huard J., Lochmuller H., Acsadi G., Jani A., Massie B., and Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. (1995) 107-115
18. van der Eb M.M., Cramer S.J., Vergouwe Y., Schagen F.H., van Krieken J.H., van der Eb A.J., Borel Rinkes I.H., van de Velde C.J., and Hoeben R.C. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. 5 (1998) 451-458
19. Reynolds P., Dmitriev I., and Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther. 6 (1999) 1336-1339
20. Bilbao R., Gerolami R., Bralet M.P., Quan C., Tran P.L., Tennant B., Prieto J., and Bréchot C.T. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther. 7 (2000) 657
21. Vorburger S.A., and Hunt K.K. Adenoviral gene therapy. Oncologist 7 (2002) 46-59
22. Kay M.A., Holterman A.X., Meuse L., Gown A., Ochs H.D., Linsley P.S., and Wilson C.B. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Iα administration. Nat. Genet. 11 (1995) 191-197
23. Hallenbeck P.L., and Stevenson S.C. Targetable gene delivery vectors. Adv. Exp. Med. Biol. 465 (2000) 37-46
24. Bangari D.S., and Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6 (2006) 215-226
25. Rein D.T., Breidenbach M., and Curiel D.T. Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2 (2006) 137-143
26. Kanerva A., and Hemminki A. Adenoviruses for treatment of cancer. Ann. Med. 37 (2005) 33-43
27. Worgall S., Wolff G., Falck-Pedersen E., and Crystal R.G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8 (1997) 37-44
28. Yang Y., Li Q., Ertl H.C., and Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69 (1995) 2004-2015
29. Kim M., Zinn K.R., Barnett B.G., Sumerel L.A., Krasnykh V., Curiel D.T., and Douglas J.T. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 38 (2002) 1917-1926
30. Stone D., Ni S., Li Z.Y., Gaggar A., DiPaolo N., Feng Q., Sandig V., and Lieber A. Development and assessment of human adenovirus type 11 as a gene transfer vector. J. Virol. 79 (2005) 5090-5104
31. Tomko R.P., Xu R., and Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3352-3356
32. Kanerva A., Wang M., Bauerschmitz G.J., Lam J.T., Desmond R.A., Bhoola S.M., Barnes M.N., Alvarez R.D., Siegal G.P., Curiel D.T., and Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Molec. Ther. 5 (2002) 695-704
33. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., and Finberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275 (1997) 1320-1323
34. Mueck A.O., Seeger H., and Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?. Life Sci. 75 (2004) 1205-1210
35. Noureddini S.C., and Curiel D.T. Genetic targeting strategies for adenovirus. Mol. Pharmacol. 2 (2005) 341-347
36. Dmitriev I., Krasnykh V., Miller C.R., Wang M., Kashentseva E., Mikheeva G., Belousova N., and Curiel D.T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72 (1998) 9706-9713
37. Cripe T.P., Dunphy E.J., Holub A.D., Saini A., Vasi N.H., Mahller Y.Y., Collin M.H., Snyde J.D., Krasnykh V., Curiel D.T., Wickham T.J., DeGregori J., Bergelson J.M., and Currier M.A. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61 (2001) 2953-2960
38. Mercier G.T., Campbell J.A., Chappell J.D., Stehle T., Dermody T.S., and Barry M.A. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 6188-6193
39. Glasgow J.N., Bauerschmitz G.J., Curiel D.T., and Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr. Gene Ther. 4 (2004) 1-14
40. Vile R.G., Sunassee K., and Diaz R.M. Strategies for achieving multiple layers of selectivity in gene therapy. Mol. Med. Today 4 (1998) 84-92
41. Vassaux G. New cloning tools for the design of better transgenes. Gene Ther. 6 (1999) 307-308
42. Pruzan R., Chatterjee P.K., and Flint S.J. Specific transcription from the adenovirus E2E promoter by RNA polymerase III requires a subpopulation of TFIID. Nucleic Acids Res. 20 (1992) 5705-5712
43. Chen X., Wu J., Hornischer K., Kel1 A., and Wingender E. TiProD: the Tissue-specific Promoter Database. Nucleic Acids Research 34 (2006) [Database]
44. Stoff-Khalili M.A., Stoff A., Rivera A.A., Mathis J.M., Everts M., Wang M., Kawakami Y., Waehler R., Mathew Q.L., Yamamoto M., Rocconi R.P., Siegal G.P., Richter D.F., Dall P., Zhu Z.B., and Curiel D.T. Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biol. Ther. 4 (2005) 1203-1210
45. Zhu Z.B., Makhija S.K., Lu B., Wang M., Wang S., Takayama K., Siegal G.P., Reynolds P.N., and Curiel D.T. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J. Thorac. Oncol. 1 (2006) 701-711
46. Heise C., and Kirn D.H. Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. 105 (2000) 847-851
47. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. 105 (2000) 1169-1172
48. Rocconi R.P., Zhu Z.B., Stoff-Khalili M., Rivera A.A., Lu B., Wang M., Alvarez R.D., Curiel D.T., and Makhija S.K. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gynecol. Oncol. 105 (2007) 113-121
49. Haviv Y.S., and Curiel D.T. Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr. Gene Ther. 3 (2003) 357-385
50. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2 (2003) 157-160
51. Freytag S.O., Barton K.N., Brown S.L., Narra V., Zhang Y., Tyson D., Nall C., Lu M., Ajlouni M., Movsas B., and Kim J.H. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Molec. Ther. 15 (2007) 1600-1606
52. Fueyo J., Gomez-Manzano C., Alemany R., Lee P.S., McDonell T.J., Mitlianga P., Shi Y.X., Levin V.A., Yung W.K., and Kyritis A.P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19 (2000) 2-12
53. Russell W.C. Update on adenovirus and its vectors. J. Gen. Virol. 81 (2000) 2573-2604
54. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
55. Rosenfeld M.E., and Curiel D.T. Gene therapy strategies for novel cancer therapeutics. Curr. Opin. Oncol. 8 (1996) 72-77
56. Elledge R.M., and Alfred D.C. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res. Treat. 32 (1994) 39-47
57. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol. Ther. 4 (2005) 512-517
58. Wantanabe M., Nasu Y., and Kashiwakura Y. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum. Gene Ther. 16 (2005) 699-710
59. Othman E.E., Salama S., Ismail N., and Al-Hendy A. Toward gene therapy of endometriosis: adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells. Fertil. Steril. 88 (2007) 462-471
60. Salama S., Kamel M., Christman G., Wang H., and Al-Hendy A. Gene therapy of uterine fibroids: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells. Gynecol. Obstet. Investig. 63 (2007) 61-70
61. Wack S., Rejiba S., Parmentier C., Aprahamian M., and Hajri A. Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Molec. Ther. 16 (2008) 252-260
62. Cai K.X., Tse L.Y., Leung C., Tam P.K., Xu R., and Sham M.H. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. Clin. Cancer Res. 14 (2008) 939-949
63. Britz-Cunningham S.H., and Adelstein S.J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 44 (2003) 1945-1961
64. Greco O., and Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 187 (2001) 22-36
65. Tepper R.I., and Mule J.J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5 (1994) 153-164
66. Döhring C., Angman L., Spagnoli G., and Lanzavecchia A. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 57 (1994) 754-759
67. Dummer R., Yue F.Y., Pavlovic J., Geertsen R., Döhring C., Moelling K., and Burg G. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br. J. Cancer 77 (1998) 1413-1419
68. Dalgleish A. The case for therapeutic vaccines. Melanoma Res. 6 (1996) 5-10
69. Wijayahadi N., Haron M.R., Stanslas J., and Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J. Chemother. 19 (2007) 716-723
70. Abonour R., Williams D.A., Einhorn L., Hall K.M., Chen J., Coffman J., Traycoff C.M., Bank A., Kato I., Ward M., Williams S.D., Hromas R., Robertson M.J., Smith F.O., Woo D., Mill B., Srour E.F., and Cornetta K. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat. Med. 6 (2000) 652-658
71. Cowan K.H., Moscow J.A., Huang H., Zujewski J.A., O'Shaughnessy J., Sorrentino B., Hines K., Carter C., Schneider E., Cusack G., Noone M., Dunbar C., Steinberg S., Wilson W., Goldspiel B., Read E.J., Leitman S.F., McDonagh K., Chow C., Abati A., Chiang Y., Chang Y.N., Gottesman M.M., Pastan I., and Nienhuis A. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin. Cancer Res. 5 (1999) 1619-1628
72. Takebe N., Zhao S.C., Adhikari D., Mineishi S., Sadelain M., Hilton J., Colvin M., Barnerjee D., and Bertino J.R. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Molec. Ther. 3 (2001) 88-96
73. Farwell S.E., Lees J.A., White R., and Parker M.G. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60 (1990) 953-962
74. Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Annu. Rev. Genet. 25 (1991) 89-123
75. Wrenn C.K., and Katzenellenbogen B.S. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J. Biol. Chem. 268 (1998) 24089-24098
76. Katzenellenbogen B.S., Bhardwaj B., Fang H., Ince B.A., Pakdel F., Reese J.C., Schodin D., and Wren C.K. Hormone binding and transcription activation by estrogen receptors: analyses using mammalian and yeast systems. J. Steroid Biochem. Mol. Biol. 47 (1993) 39-48
77. Danielian P.S., White R., Hoare S.A., Fawell S.F., and Parker M.G. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol. 7 (1993) 232-240
78. Ince B.A., Schodin D.J., Shapiro D.J., and Katzenellenbogen B.S. Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors. Endocrinology 136 (1995) 3194-3199
79. Ince B.A., Zhuang Y., Wrenn C.K., Shapiro D.J., and Katzenellenbogen B.S. Powerful dominant negative mutants of the human estrogen receptor. J. Biol. Chem. 268 (1993) 14026-14032
80. Chien P.Y., Ito M., Park Y., Tagami T., Gehm B.D., and Jameson J.L. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells. Mol. Endocrinol. 13 (1999) 2122-2136
81. Lazennec G., Alcorn J.L., and Katzenellenbogen B.S. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol. Endocrinol. 13 (1999) 969-980
82. Lee E.J., Duan W.R., Jakacka M., Gehm B.D., and Jameson J.L. Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology 142 (2001) 3756-3763
83. Tasciotti E., Zoppe M., and Giacca M. Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat. Cancer Gene Ther. 10 (2003) 64-74
84. Reid R., Mar E.C., Huang E.S., and Topal M.D. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human-alpha and human-beta polymerases: a unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J. Biol. Chem. 263 (1988) 3898-3904
85. Robe P.A., Princen F., Martin D., Malgrange B., Stevenaert A., Moonen G., Gielen J., Merville M.P., and Bours V. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3′,5′-cyclic monophosphate, A-glycyrrhetinic acid, and cytosine arabinoside. Biochem. Pharmacol. 60 (2000) 241-249
86. Palu G., Cavaggioni A., Calvi P., Franchin E., Pizzato M., Boschetto R., Parolin C., Chilosi M., Ferrini S., Zanusso A., and Colombo F. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. 6 (1999) 330-337
87. Rubsam L.Z., Boucher P.D., Murphy P.J., KuKuruga M., and Shewach D.S. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59 (1999) 669-675
88. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., and Abraham G.N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53 (1993) 5274-5283
89. Smythe W.R., Hwang H.C., Elshami A.A., Amin K.M., Eck S.L., Davidson B.L., Wilson J.M., Kaiser L.R., and Albelda S.M. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222 (1995) 78-86
90. Mesnil M., and Yamasaki H. By stander effect in herpes simplex virus-thymidine kinase/gancilovir cancer gene therapy; role of gap junctional intercellular communication. Cancer Res. 60 (2000) 3989-3999
91. Evans P., and Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am. Fam. Phys. 75 (2007) 1503-1508
92. Surrey E.S., Lietz A.K., and Schoolcraft W.B. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil. Steril. 75 (2001) 405-410
93. Chryssikopoulos A., and Loghis C. Indications and results of total hysterectomy. Int. Surg. 71 (1986) 188-194
94. Velebil P., Wingo P.A., Xia Z., Wilcox L.S., and Peterson H.B. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet. Gynecol. 86 (1995) 764-769
95. Andreyko J.L., Marshall L.A., Dumesic D.A., and Jaffe R.B. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet. Gynecol. Surv. 42 (1987) 1-21
96. Lefebvre G., Vilos G., Allaire C., Jeffrey J., Arneja J., Birch C., Fortier M., and Wagner M.S. The management of uterine leiomyomas. J. Obstet. Gynaecol. Can. 25 (2003) 396-418
97. Marret H., Lansac J., and Fourquet F. Transvaginal hysterectomy: not always the rational approach for leiomyomas. Eur. J. Obstet. Gynecol. Reprod. Biol. 120 (2005) 232-233
98. Kettel L.M., Murphy A.A., Morales A.J., and Yen S.S.C. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum. Reprod. 9 (1994) 116-120
99. Vercellini P., Maddalena S., De Giorgi O., Aimi G., and Crosignani P.G. Abdominal myomectomy for infertility: a comprehensive review. Hum. Reprod. 13 (1998) 873-879
100. Payne J.F., and Haney A.F. Serious complications of uterine artery embolization for conservative treatment of fibroids. Fertil. Steril. 79 (2003) 128-131
101. Goodwin S.C., and Walker W.J. Uterine artery embolization for the treatment of uterine fibroids. Curr. Opin. Obstet. Gynecol. 10 (1998) 315-320
102. Hutchins Jr. F.L., Worthington-Kirsch R., and Berkowitz R.P. Selective uterine artery embolization as primary treatment for symptomatic leiomyomata uteri. J. Am. Assoc. Gynecol. Laparosc. 6 (1999) 279-284
103. Niu H., Simari R.D., Zimmermann E.M., and Christman G.M. Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet. Gynecol. 91 (1998) 735-740
104. Al-Hendy A., Lee E.J., Wang H.Q., and Copland J.A. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogenreceptor inhibits tumor growth in nude mice. Am. J. Obstet. Gynecol. 191 (2004) 1621-1631
105. Hassan M.H., Salama S.A., Arafa H.M., Hamada F.M., and Al-Hendy A. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J. Clin. Endocrinol. Metab. 92 (2007) 3949-3957
106. M.H. Hassan, S.A. Salama, D. Zhang D, H.M. Arafa, F.A. Hamada, H. Fouad, C. Walker, A. Al-Hendy, Gene therapy targeting leiomyoma: adenovirus mediated delivery of dominant negative estrogen receptor gene shrinks uterine tumors in Eker rat model, Fertil. Steril. (in press).
107. Hassan M., Zhang D., Salama s Hamadab F., Arafa H., Fouad H., Walker C., and Al-Hendy A. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. OB. Gyn. Inv. 68 (2009) 19-32
108. Hassan M.H., Katoon N., Curiel D.T., Hamada F.M., Arafa H.M., and Al-Hendy A. Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells. Hum. Reprod. 23 (2008) 514-524
109. Verma I.M., and Weitzman M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74 (2005) 711-738
110. Journal of Gene Medicine website at http://www.wiley.co.uk/wileychi/genmed.
111. Sterman D.H., Recio A., Vachani A., Sun J., Cheung L., DeLong P., Amin K.M., Litzky L.A., Wilson J.M., Kaiser L.R., and Albelda S.M. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin. Cancer Res. 11 (2005) 7444-7453
112. Nasu Y., Saika T., Ebara S., Kusaka N., Kaku H., Abarzua F., Manabe D., Thompson T.C., and Kumon H. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Molec. Ther. 15 (2007) 834-840
113. Mincheff M., Tchakarov S., Zoubak S., Loukinov D., Botev C., Altankova I., Georgiev G., Petrov S., and Meryman H.T. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur. Urol. 38 (2000) 208-217
114. Stephenson J.S. Genetically modified viruses: vaccines by design. Curr. Pharm. Biotechnol. 2 (2001) 47-76
115. Stribley J.M., Rehman K.S., Niu H., and Christman G.M. Gene therapy and reproductive medicine. Fertil. Steril. 77 (2002) 645-657
116. Nielsen L.L., Lipari P., Dell J., Gurnani M., and Hajian G. Adenovirus mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 4 (1998) 835-846
117. Schodin D.J., Zhuang Y., Shapiro D.J., and Katzenellenbogen B.S. Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness. J. Biol. Chem. 270 (1995) 31163-31171
118. Giudice L.C., and Kao L.C. Endometriosis. Lancet 364 (2004) 1789-1799
119. Eskenazi B., and Warner M.L. Epidemiology of endometriosis. Obstet. Gynecol. Clin. North Am. (1997) 235-258
120. Garry R., Clayton R., and Hawe J. The effect of endometriosis and its radical laparoscopic excision on quality of life indicators. BJOG 107 (2000) 44-54
121. Simoens S., Hummelshoj L., and D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum. Reprod. Updat. 13 (2007) 395-404
122. Dlugi A.M., Miller J.D., and Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group Fertil. Steril. 54 (1990) 419-427
123. Mahutte N.G., and Arici A. Medical management of endometriosis-associated pain. Obstet. Gynecol. Clin. North Am. 30 (2003) 133-150
124. Hughes E., Brown J., Collins J.J., Farquhar C., Fedorkow D.M., and Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst. Rev. 18 (2007) (CD000155)
125. Ferrero S., Abbamonte L.H., Anserini P., Remorgida V., and Ragni N. Future perspectives in the medical treatment of endometriosis. Obstet. Gynecol. Surv. 60 (2005) 817-826
126. Dabrosin C., Gyorffy S., Margetts P., Ross C., and Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am. J. Pathol. 161 (2002) 909-918
127. Lee E.J., Duan W.R., Jakacka M., Gehm B.D., and Jameson J.L. Dominant negative ER induces apoptosis in GH (4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology 142 (2001) 3756-3763
128. Seli E., and Arici A. Endometriosis: interaction of immune and endocrine systems. Semin. Reprod. Med. 21 (2003) 135-144
129. Zhu Z.B., Makhija S.K., Lu B., Wang M., Kaliberova L., Liu B., Rivera A.A., Nettelbeck D.M., Mahasreshti P.J., Leath C.A., Barker S., Yamaoto M., Li F., Alvarez R.D., and Curiel D.T. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 11 (2004) 256-262
130. Othman E.E., Zhu Z.B., Curiel D.T., Khatoon N., Salem H.T., Khalifa E.A., and Al-Hendy A. Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells. Am. J. Obstet. Gynecol. 199 (Aug 2008) 117e1-6
131. Schagen F.H., Wensveen F.M., Carette J.E., Dermody T.S., Gerritsen W.R., and Beusechem v.a.n.V.W. Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein. Molec. Ther. 13 (2006) 997-1005
132. Kanerva A., Mikheeva G.V., Krasnykh V., Coolidge C.J., Lam J.J., Mahasreshti P., Barker S.D., Straughn M., Barnes M.N., Alvarez R.D., Hemminki A., and Curiel D.T. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8 (2002) 275-280
133. Van Houdt W.J., Haviv Y.S., Lu B., Wang M., Rivera A.A., Ulasov I.V., Lamfers M.L., Rein D., Lesniak M.S., Siegal G.P., Dirven C.M., Curiel D.T., and Zhu Z.B. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J. Neurosurg. 104 (Apr 2006) 583-592
134. Barker S.D., Coolidge C.J., Kanerva A., Hakkarainen T., Yamamoto M., Liu B., Rivera A.A., Bhoola S.M., Barnes M.N., Alvarez R.D., Curiel D.T., and Hemminki A. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J. Gene Med. 5 (2003) 300-310
135. Breidenbach M., Rein D.T., Schondorf T., Khan K.N., Herrmann I., Schmidt T., Reynolds P.N., Vlodavsky I., Haviv Y.S., and Curiel D.T. A new targeting approach for breast cancer gene therapy using the heparanase promoter. Cancer Lett. 18 (2006) 114-122
136. Hoffman P.J., Milliken D.B., Gregg L.C., Davis R.R., and Gregg J.P. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil. Steril. 82 (2004) 639-649
137. Di Lieto A., DeFalco M., Pollio F., Mansueto G., Salvatore G., Somma P., Ciociolo F., DeRosa G., and staibano S. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J. Soc. Gynecol. Investig. 12 (2005) 123-128
138. Gentry C.C., Okolo S.O., Fong L.F., Crow J.C., Maclean A.B., and Perrett C.W. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin. Sci. (Lond) 101 (2001) 691-695
139. Hong T., Shimada Y., Uchida S., Itami A., Li Z., Ding Y., Kaganoi J., Komoto I., Sukurai T., and Imamura M. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int. J. Mol. Med. 8 (2001) 141-148
140. Hyder S.M., Huang J.C., Nawaz Z., Boettger-Tong H., Makela S., Chiappetta C., and Stancel G.M. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ. Health Perspect. 108 (2000) 785-790